Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Shares Outstanding (Diluted Average): 2011-2025

Historic Shares Outstanding (Diluted Average) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $27.9 million.

  • Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) fell 0.45% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 0.45%. This contributed to the annual value of $27.3 million for FY2024, which is 2.71% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Shares Outstanding (Diluted Average) of $27.9 million as of Q3 2025, which was up 0.81% from $27.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $31.1 million in Q1 2024 and a low of $26.0 million during Q1 2021.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $27.8 million, with a median of $27.6 million in 2025.
  • Per our database at Business Quant, Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) spiked by 30.69% in 2021 and then declined by 11.30% in 2025.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $26.0 million in 2021, then rose by 0.39% to $26.3 million in 2022, then increased by 1.14% to $26.6 million in 2023, then rose by 2.71% to $27.3 million in 2024, then fell by 0.45% to $27.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $27.9 million in Q3 2025, compared to $27.7 million in Q2 2025 and $27.6 million in Q1 2025.